皇冠hga025大学洛杉矶分校神经内分泌肿瘤项目
找到你的关怀
You can trust 皇冠hga025大学洛杉矶分校健康 to deliver an accurate diagnosis and outstanding care using the latest advances in nuclear medicine. 呼叫 310-794-1005 与专家联系.
皇冠hga025大学洛杉矶分校神经内分泌肿瘤
We make a difference every day in the lives of patients and their loved ones who are affected by neuroendocrine tumors (NET). The UCLA NET team is dedicated to providing the best possible care from the time that patients are diagnosed throughout their treatment and follow-up period. Our expert physicians and nurses work closely with specialists throughout UCLA to achieve the most successful outcomes.
皇冠hga025大学洛杉矶分校在外科领域有着良好的记录, 医学肿瘤学, 胃肠病学, 内分泌学和影像学. Our faculty includes nationally and internationally renowned experts in the diagnosis and treatment of neuroendocrine tumors. In 2015, the comprehensive resources at UCLA coalesced to form a dedicated Neuroendocrine Tumor Program. The UCLA NET team brings together clinicians in all disciplines involved in taking care of patients with neuroendocrine tumors. 该团队提供世界一流的病人护理, which includes an interdisciplinary tumor board that reviews all patient cases. This joint effort has led to UCLA becoming one of the few expanded access Investigational New Drug trial sites for peptide receptor radionuclide therapy in the U.S.
神经内分泌肿瘤
Neuroendocrine tumors are a heterogeneous group of epithelial neoplasms (abnormal growth of tissue) that originate in hormone-producing cells of the body's neuroendocrine system. As neuroendocrine cells are in almost every organ of the body, net几乎可以出现在任何地方, 包括消化系统, 胰腺和肺. NETs can show different biological behavior, appearance and response to therapy. Those variances largely depend on their location, hormone production and cell characteristics.
NETs can be grouped by their status as hormone-producing or non-hormone-producing tumors. They can also be classified by their growth rate as well-differentiated or poorly differentiated tumors. Well-differentiated NETs tend to be more biologically indolent (slow to develop) and poorly differentiated NETs — including small cell or large cell neuroendocrine carcinoma — can exhibit more rapid clinical progression. A widely used tool to measure the proliferation rate is Ki-67 (a nuclear protein involved in the cell-cycle regulation). A Ki-67 tumor of less than 3 percent is defined as low-grade (G1); 3 to 20 percent is considered intermediate-grade (G2); and greater than 20 percent is high-grade (G3). Low- and intermediate-grade tumors are considered well-differentiated tumors.
优质护理
我们提供外科专家的诊断和治疗, 医学肿瘤学, 胃肠病学, 病理, radiology and nuclear medicine who are dedicated to treating patients with NETs. 治疗 decisions are based on a discussion for each patient by the tumor board, 考虑到最先进的治疗方法, 创新研究方案和循证医学. We offer patients the most comprehensive care possible to treat NETs by leveraging our world-class programs for pancreas diseases, 肝脏移植手术, 癌症和核医学.
治疗
Our team is committed to finding the best treatment for each patient. Multiple options are available depending on the type, location and extent of disease. This allows each patient's case to be discussed at our NET tumor board and multidisciplinary meetings. We are the only institution in the region to offer patients comprehensive care, from state-of-the-art PET diagnostics to radiation therapy to 肝脏移植手术ation. 治疗方案包括:
- This includes minimally invasive procedures using laparoscopy or laparotomy. 如果整个肿瘤不能安全切除, 可以考虑手术切除肿瘤.
- 放射治疗. High X-rays or other particles are used to eliminate cancer cells. This is done either by external-beam radiation therapy (where radiation is administered from outside the body) or internal/brachytherapy radiation therapy (where implants inside the body are used for treatment).
- Uses toxic drugs that interfere with the growth of cancer cells and results in destroying those cells.
- 射频消融术. Radiofrequency waves are used to kill cancer cells in a defined area.
- 靶向治疗. Targets certain areas of the cancer cell or its environment (including genes and proteins) that are responsible for the growth and/or survival of the tumor.
- 激素疗法. 药物可以减少肿瘤产生的激素. Suitable for patients with symptoms caused by hormone release from the neuroendocrine tumor.
- 肽受体放射性核素治疗. A cell-targeting protein (or peptide) is combined with a small radionuclide (or radioactive material). 这种激素样药物是静脉注射的. It travels to the tumor cells and delivers a high dose of radiation to destroy the tumor.
- Theranostics (nuclear medicine diagnostics and therapeutics) (310) 794-1005
- 约翰内斯·切尔宁博士, 分子成像核医学, Chief of the Ahmanson Translational Theranostics Division at UCLA
- 马丁·奥尔巴赫,医学博士核医学
- Andrew Quon,医学博士核医学
- 朱塞佩·卡卢奇放射药学,放射化学
- 放射科(310)301-6800
- Barbara Kadell,医学博士放射诊断学
- 陆大卫,医学博士放射诊断学
- 史蒂文·拉曼,医学博士放射诊断学
- 外科(310)794-7788
- Timothy Donahue,医学博士,普通外科(GI,胰腺)
- 马克·吉吉斯,医学博士,普通外科(GI,胰腺)
- 乔·海恩斯,医学博士 普通外科(GI、胰腺)
- Vatche Agopian, MD、肝脏及移植外科(肝脏)
- 医学肿瘤学
- 乔尔·伦道夫·赫克特,医学博士消化系统疾病血液学 & 肿瘤学(GI)
- 泽夫·温伯格,医学博士、血液学 & 肿瘤学(GI)
- 约翰·格拉斯皮,医学博士、血液学 & 肿瘤学
- 乔纳森·戈德曼,医学博士、血液学 & 肿瘤学(肺)
- GI/内分泌科(310)825-7922
- Anthony Heaney, MD内分泌学,糖尿病 & 新陈代谢
- Joseph Pisegna,医学博士,消化系统疾病,NET疾病
- Raman Muthusamy医学博士消化系统疾病介入内窥镜检查
- 史蒂芬·金,医学博士消化系统疾病介入内窥镜检查
- 病理学(310)267-2680
- 大卫·道森,医学博士,博士、解剖病理学 & 临床病理学
- UCLA NET团队联系电话:(310)206-6889
- 劳伦·达马托,NP, MSN,护士协调员
位置
罗纳德·里根皇冠hga025大学洛杉矶分校医疗中心
韦斯特伍德广场757号
洛杉矶,皇冠hga02590095
联系信息
For PRRT information please call Thaiza Adams at (310) 794-7741.
有关UCLA NET团队的问题, including patient issues and information about clinical trials, 请联系劳伦·达马托,电话:(310)206-6889.
Click to enlarge Westwood area map >
Other 皇冠hga025大学洛杉矶分校健康 Parking Options >
皇冠hga025 & 视频
Check out the video of the LACNETs Patient Education meeting “Focus on PRRT” on April 14, 2020.